The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Growth Fund - Series I
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neomile Growth Fund - Series I (a non-promoter entity, likely a foreign/AIF fund managed by Neomile Asset Managers) sold 4,07,255 equity shares of Anlon Healthcare Ltd (0.76% of total share capital) through open market transactions between 8th March 2026 and 10th March 2026. As a result, the fund's holding in the company declined from 27,45,296 shares (5.16%) to 23,38,041 shares (4.40%). This is a routine SAST disclosure triggered because the fund's holding crossed below the 5% threshold as a result of the sale.
The fund reduced its stake below the 5% mark, which may be interpreted as a mild negative signal indicating reduced institutional conviction. However, since the entity is not a promoter and the sale was relatively small, the impact on share price is likely limited. Retail investors should watch for further disclosures to see if this trend continues.